Diarylalkylamine REV-ERB antagonists and their use as medicaments

Fondazione Istituto Italiano di Tecnologia; Benedetto GRIMALDI; Esther TORRENTE; Rita SCARPELLI; Giovanni BOTTEGONI; Tiziano BANDIERA; Marina VERONESI

Diarylalkylamine REV-ERB antagonists and their use as medicaments

Fondazione Istituto Italiano di Tecnologia (Inventor), Benedetto GRIMALDI (Inventor), Esther TORRENTE (Inventor), Rita SCARPELLI (Inventor), Giovanni BOTTEGONI (Inventor), Tiziano BANDIERA (Inventor), Marina VERONESI (Inventor)

Pharmacy

Research output: Patent

Abstract

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof : It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and pro-apoptotic agents for cancer therapy.

Original language	English
Patent number	WO2015/52283
Publication status	Published - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@misc{59d0f1458cc949feb7ce6d6e9ecae5bb,

title = "Diarylalkylamine REV-ERB antagonists and their use as medicaments",

abstract = "The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof : It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and pro-apoptotic agents for cancer therapy.",

author = "{Fondazione Istituto Italiano di Tecnologia} and Benedetto GRIMALDI and Esther TORRENTE and Rita SCARPELLI and Giovanni BOTTEGONI and Tiziano BANDIERA and Marina VERONESI",

year = "2015",

language = "English",

type = "Patent",

note = "WO2015/52283",

}

TY - PAT

T1 - Diarylalkylamine REV-ERB antagonists and their use as medicaments

AU - Fondazione Istituto Italiano di Tecnologia

AU - GRIMALDI, Benedetto

AU - TORRENTE, Esther

AU - SCARPELLI, Rita

AU - BOTTEGONI, Giovanni

AU - BANDIERA, Tiziano

AU - VERONESI, Marina

PY - 2015

Y1 - 2015

N2 - The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof : It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and pro-apoptotic agents for cancer therapy.

AB - The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof : It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and pro-apoptotic agents for cancer therapy.

M3 - Patent

M1 - WO2015/52283

ER -

Diarylalkylamine REV-ERB antagonists and their use as medicaments

Abstract

UN SDGs

Fingerprint

Cite this